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Background: Studies performed in high-HIV prevalence countries showed a strong epidemiological association
between male circumcision (MC) and the prevention of HIV transmission. We estimated the potential impact of MC
on the general heterosexual population in low-HIV prevalence countries.
Methods: Cross-national comparisons, including data on newly diagnosed HIV cases among heterosexuals living in
Israel (where almost all males undergo MC), to similar data from the Netherlands and France (where <10 % of
males are circumcised) were performed. National data from HIV registers and Bureaus of Statistics for the period of
2004–2010, global rates, rates by sex, age, and year of HIV-diagnosis were compared. MC and potential biases were
examined.
Results: Annual rates of new HIV diagnoses per 100,000 were significantly lower in Israel compared to the
Netherlands and France (for men: 0.26–0.70, 1.91–2.28, and 2.69–3.47, respectively; for women: 0.10–0.34, 1.10–2.10
and 2.41–3.08, respectively). Similarly, HIV-rates were much lower in Israel when comparing by age groups.
Although Gross National Income per capita in 2010 was lower in Israel compared to the Netherlands and France,
access to HIV testing and treatment were not different between countries. Also, the number of sexual-partners and
condom-use in the general population showed a high similarity between the countries.
Conclusions: The lower rate of HIV among heterosexuals in Israel compared to the Netherlands and France might
be explained by MC routinely practiced in Israel, since other parameters of influence on HIV transmission were
rather similar between the countries. However, recommendation for systematic MC in low HIV prevalence countries
requires further investigations.
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The impact of male circumcision (MC) in the prevention
of HIV transmission is still being investigated [1, 2].
Various observational studies and three randomized con-
trolled trials (RCTs) performed in developing countries
characterized by high level of HIV prevalence, showed a
strong epidemiological association between MC and the
prevention of heterosexual HIV transmission in men [2].
As a result, the World Health Organization (WHO)/* Correspondence: daniel.chemtob@moh.health.gov.il
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creativecommons.org/publicdomain/zero/1.0/UNAIDS recommended MC as one of the public health
methods for HIV prevention in high-prevalence countries
[3]. However, studies on the impact of MC in low-
prevalence HIV countries are few, apart from a few studies
among men having sex with men (MSM) in the United
States (US) [4]. Although modeling studies show that MC
could prevent 2 million infections globally over a 10-year-
period; to date it is assumed that “MC is not an appropri-
ate public-health intervention strategy for Europe” [5].
Further, there is uncertainty whether the recommendation
of MC among heterosexuals in sub-Saharan Africans article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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by lower HIV-prevalence rates. We hypothesized that, as a
result of a high rate of MC practiced in Israel, HIV popu-
lation rates would be lower in Israel compared to other
low HIV prevalence countries (i.e. France and the
Netherlands) with a low rate of MC practice.
The major aim of this study was to estimate, for the
first time, the potential impact of MC on HIV in the
general heterosexual population in low HIV endemic
countries. Secondly, our data may help future model-
ing of the impact of MC on HIV transmission in low-
prevalence countries.
Methods
This ecological study compares nationwide HIV data from
Israel, a country where almost all males are circumcised [7]
to nationwide HIV data from the Netherlands and France,
where only a minority of males are circumcised [8, 9], and
Personal communication Dutch Foundation for Circumci-
sion, www.besnijdeniscentrum.nl.
New HIV diagnosis among heterosexual males and
females
The rates of heterosexual newly diagnosed with HIV in
Israel and in France and the Netherlands were compared
by dividing heterosexuals as indicated in the National
HIV registers with the relevant data from the central
bureaus of statistics for 2004–2010 [8, 10, 11] in each
country. Other key-risk groups for HIV-transmission, as
described by the WHO-EURO and ECDC [12], such as
MSM, Injecting Drug Users (IDU), immigrants originat-
ing from countries with generalized epidemics (GE), and
persons with an unknown mode of transmission were
excluded from the analyses. HIV infection rates were
stratified by gender, age group (15–24, 25–34, 35–44,
45–54) and year of diagnosis (2004–2010).
As denominator, we used the demographic data (gender
and age groups) from the central bureaus of statistics for
2004–2010 [8, 10, 11].
Extent of MC
The proportion of MC in each country was estimated from
published and unpublished data available in each country,
and according to the proportion of minorities known to
practice MC on a religious or cultural basis [7, 9].
Economic development
As a measure of economic development of these three
westernized countries we used the Gross National Income
(GNI) per capita at nominal values, according to the Atlas
Method, an indicator of income developed by the World
Bank. The GNI per capita is the dollar value of a country’s
final income in a year, divided by its population. It reflects
the average income of a country’s citizens [13].Access to HIV health care
The access was estimated by the coverage of combination
antiretroviral therapy (cART) among HIV-diagnosed
people. We used national data as collected and described
by the WHO-Europe for the European Region [14].
HIV testing and sexual behavioral patterns
Access to HIV testing was compared using the ECDC
report [12] and national data.
Sexual risk behaviors (such as number of sexual partners,
and condom use) were compared by using relevant publica-
tions from the 3 countries. Data for Israel [15] were re-
trieved from a National survey performed in 2000 using a
sampling (n = 800) of the Israeli adults aged 18–45. Data
from the Netherlands came from behavioural surveillance
studies called ‘Sexual Health in the Netherlands’ in 2006
[16] conducted on representative samples (n = 4,147) of the
Dutch population aged 15–70, and data from France came
from two national telephone probability surveys performed
in 2006 on a sample of 12,364 subjects aged 18–69 years
[17] and 5,071 participants in 2004 aged 18–69 years [18].
Lastly, estimations of the proportion of people living with
HIV/AIDS (PLWHA) who are unaware of their HIV status
already existed (for Israel [19], the Netherlands [20], and
France [21]).
Results
Newly diagnosed HIV rates among heterosexual females
and males
When comparing the three countries for the period of
2004–2010, annual rates of new HIV diagnoses were gen-
erally much lower in Israel, both among men and women
(Table 1), followed by the Netherlands and France.
In Israel, the Netherlands and France, annual HIV rates
(per 100,000) among men ranged between 0.26–0.7, 1.91–
2.28, and 2.69–3.47, respectively (Table 1). For women, the
annual rates were 0.1–0.34, 1.10–2.10 and 2.41–3.08, re-
spectively (Table 1).
When comparing Israel to the Netherlands (all age
groups together), global annual rates among Dutch het-
erosexual men and women were 3–7 times and 2–14
times higher, respectively. When the same rates were
compared for Israel and France, rates in France were 4–11
and 7–30 times higher, respectively (Table 1).
When comparing by age groups between the three
countries, the rate of new HIV diagnoses is much lower
in Israel than in the Netherlands and France for each
year of diagnosis, both for men and women.
In Israel, the rate of new HIV diagnoses was always
under 1.09/100,000, irrespective of gender, age and year of
HIV diagnosis. For males, the highest rate in Israel was
1.09 (males aged 45–54 in 2008); in the Netherlands 3.2
(males aged 35–44 in 2005); and in France 5.18 (males
aged 35–44 in 2004). For females, the highest rate in Israel
Table 1 Newly diagnosed HIV cases among heterosexual, males
and female, aged 15–54, living in Israel, France or Netherlands,
not originated from countries with a generalized epidemic
(2004–2010) – Absolute numbers and incident rates of new
diagnoses (by 100,000 population)
Year of
diagnosis
Gender Israel The Netherlands France
No. Rate No. Rate No. Rate
2004 Male 10 0.54 66 1.80 586 3.47
Female 2 0.1 48 1.35 528 3.08
2005 Male 7 0.37 75 2.06 584 3.46
Female 8 0.42 74 2.10 518 3.02
2006 Male 10 0.52 69 1.91 572 3.39
Female 2 0.1 50 1.42 459 2.67
2007 Male 5 0.26 71 1.97 540 3.2
Female 4 0.2 45 1.30 426 2.48
2008 Male 7 0.36 78 2.20 552 3.27
Female 2 0.1 37 1.08 418 2.44
2009 Male 14 0.7 73 2.07 557 3.31
Female 3 0.15 42 1.23 411 2.41
2010 Male 10 0.49 80 2.28 452 2.69
Female 7 0.34 45 1.32 410 2.41
Table 2 Average total population (from National CBS) and gross
national income (GNI) (from the World Bank [13]), in 2010
Country Average total
population 2010









France 64,855,337 34,750 23
N.B: A country is estimated by World Bank to be of high income when GNI is
US $ 12,196 or more
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2.58 (females aged 25–34 in 2005); and in France 4.63 (fe-
males aged 25–34 in 2004).
The extent of male circumcision in each country
In Israel (approximately 7.7 million inhabitants), there were
some 85,415 Jewish, Muslim and Christian male live infant
births in 2010 [10], and almost all male infant/children
were circumcised traditionally [7]. In addition, from 1989
to 2006, over 70,000 hospital/clinic based MC (mainly in
adults) were performed among Jewish new immigrants
from Eastern Europe and Ethiopia (age range: 6 months–
94 years) [7].
In France and the Netherlands, male circumcision, often
performed for medical or hygienic reasons, remains a mar-
ginal practice. Neither reliable nor relevant sources of offi-
cial national statistics on MC are available in both
countries. However, in the Dutch circumcision centres,
16,000 circumcisions are conducted annually among boys
and adult men: in 60–70 % of the cases for medical reasons;
4–5 % among adult male [Personal communication Dutch
Foundation for Circumcision, www.besnijdeniscentrum.nl)].
Furthermore, in the Netherlands (16.6 million inhabi-
tants in 2010) and in France (64.9 million in 2010), MC
was essentially found among Muslims (~850.000 (2007)
and ~5–7 million, respectively) and Jews (~ 52,000 (2009)
and ~650,000, respectively), due to cultural or religious
reasons, and it is estimated that almost all Jewish and
Muslims men are circumcised [8, 9, and Personalcommunication Dutch Foundation for Circumcision,
www.besnijdeniscentrum.nl]. Therefore, the assumptions
based on numbers of Jews and Muslims in the
Netherlands and France are that only a minority of males
(<10 %) are circumcised.
Measure of economic development and access to cART
A country is estimated by World Bank to be a high in-
come country when gross national income (GNI) is US
$ 12,196 or more. This was the case for all 3 countries
in 2010 (Table 2) in an estimation done for 219 coun-
tries and economies [13].
Compared to developing countries, access to antiretro-
viral treatment in Israel, the Netherlands and France is
expected to be highly sufficient [14].
HIV testing patterns and sexual behavioral patterns in
each country
Although it was not always possible to compare all sex-
ual patterns in all three countries by exactly the same
cut-off, data were retrieved from national surveys per-
formed in each of the three countries (Tables 3 and 4).
The proportion of patients who have ever been tested
for HIV in Israel was higher in men than in women
(Table 3). The proportion of individuals who were tested
for HIV during the past year was higher in Israel,
followed by France (approximately 15 % and 10.5 %,
respectively), and less than 10 % in Netherlands (irre-
spective of gender).
The reported number of sex partners for men and
women over the past months is roughly comparable in
the three countries, although the indicators are not
exactly similar: about 1.2–1.5 partners are reported by
men in France and in Israel whilst in the Netherlands
72 % of men declare only having one partner. The use of
condoms at last intercourse is also similar in France and
in the Netherlands among men and women 27 vs. 21 %,
19 vs. 16 %, respectively) (Table 4).
Access to HIV testing
The number of tests per 1,000 population in 2010 was
76.9 for France (the highest rate in the European Union),
Table 3 HIV testing patterns in Israel, the Netherlands and France
Underwent HIV test ever % Underwent HIV test in
the past year %
References, year of survey
Israel
Women: 32 % 15 % for women and men Ref. [15], 2000
Men: 36 % Survey among general population 18–45 years olds
The Netherlands Data only available for HIV and/or STI test ever Women: 8.0 % Ref. [16], 2006
Women: 37.4 % Men: 9.0 % Survey among general population 19–69 years olds
Men: 33.6 % Total: 8.4 %
France Women: 41.2 % Women: 14 % Ref. [18], 2004
Men: 54.9 % Men: 7.2 % Survey among general population 19–69 years olds
Total: 10.5 %
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not available [12]. In Israel, HIV testing is performed
free of charge for both Israelis and non-Israelis residents,
at primary health care clinics, HIV centers and STI cen-
ters (mostly confidential testing, but anonymous testing
is also available) [22]. In France, HIV testing is free of
charge or covered by national health insurance. More-
over, free anonymous testing is available in all regions in
France [23]. In the Netherlands access to HIV testing is
good. It has been estimated that ± 28 % of all new HIV
cases are diagnosed by general practitioners (covered by
insurance), 25 % in hospitals (covered by insurance) and
22 % at STI centres (anonymous, free of charge, opting
out testing). Remaining HIV cases are diagnosed at other
locations or by pregnancy screening [24].
Estimates of the proportion of people living with
HIV/AIDS unaware of their HIV status
The estimated proportion of people unaware of their HIV
status varies in the three countries. In Israel, based on diag-
nostic trends among each sub-population groups, it is esti-
mated that from 2002 onwards approximately 30–35 % of
cases were not aware of their HIV status [19]. In the
Netherlands and France, the estimation is 40 % (among
people aged 15–70 years, in 2008) [20] and 19 % (among
people aged 18–80 years, in 2004) [21], respectively.
Discussion
This study suggests that the rates of newly HIV diagno-
ses among heterosexuals between 2004 and 2010 in the
three developed countries may be associated with MC.
HIV rates in heterosexual males and females in Israel
were significantly lower than in the Netherlands or in
France, while the proportion of MC was much higher in
Israel [7], compared to Netherlands and France, where
only a minority of males are circumcised. Whereas the
protective effect of MC on HIV prevalence has been
demonstrated in high prevalence countries [1, 2], this isthe first time that such results were described in the
general heterosexual population in low HIV endemic
countries. Such results are of particular importance, es-
pecially considering the ongoing debate on whether MC
should be recommended as one of the public health
methods for HIV prevention in low-prevalence coun-
tries, similarly to the recommendation provided by the
WHO/UNAIDS for high-prevalence countries [3].
However, when using observational data from different
countries to show a potential protective effect of MC on
heterosexual HIV transmission, it might be difficult to
control for other factors influencing HIV transmission.
Therefore, three countries were chosen that appear to
be comparable in various aspects affecting HIV trans-
mission with the exception of the level of MC.
But first, we discuss here the possible driving forces of
an HIV epidemic in general and the situation in coun-
tries with very low HIV prevalence such as Israel. It
seems that, at least in sub-Saharan Africa, the key issue
is the structure of sexual networks, and to a lesser extent
the sexual practices themselves [25]. In other words, the
scale of an epidemic is probably very much influenced
by numbers of sexual partners, mixing patterns and con-
current partnerships, and these are more similar among
the general population compared to high risk groups.
For example, if people have sexual relations within a re-
stricted group, in an “assortative” pattern (without mixing
between various (ethnic) groups), the risk for transmitting
STI and/or HIV is presumed to be very low [26]. On the
contrary, if the partner mixing is “disassortative”, one may
have a greater risk of STI transmission. Ultimately, one
can have a mixed pattern (both “assortative” and “disassor-
tative”), such when dealing with core groups. In that case,
the core group (e.g. Commercial Sex Worker - CSW),
which is characterized by high transmission density, is
generally in relation with the core transmitter (an individ-
ual engaging in “risky” social behaviours and experience a
large proportion of diagnosed STIs - e.g, the husband, a
Table 4 Sexual behaviors and practices in Israel, Netherlands and France
Number of partners in
past fewa months
Use of condoms in
the past fewa months
Use of condoms during
the last sexual intercourse
References
Israel In the past 3 months: ‘Always or usually’ use of condom in the past 12 months: Not available [15]
Women: 1.09 Women: 17 %
Men: 1.54 Men: 34 %
Use of condom in the past 12 months:
Single with steady partner:
- Never: 50 %
- Always/usually: 22 %
Single without steady partner:
- Never: 33 %
- Always/usually: 50 %
The Netherlands In the past 6 months: Condom use in the past 6 months Women: 16 % [16]
Women: Steady partner, heterosexual contact: Men: 21 %
- 0 partner: Women:
- 17.5 % - Never: 85.2 %
- 1 partner: 73,9 % - Always/usually: 14.2 %
- > = 2 partners: 8.5 % Men:
- Never: 84.6 %
- Always/usually: 15.3 %
Men: Casual partner, heterosexual contact:
- 0 partners: 12.8 % Women:
- 1 partner: 71,7 % - Never: 51.3 % Always/usually:48.6 %
> = 2 partners: 15.5 % Men:
- Never: 26.7 %
- Always/usually:73.3 %
France In the past 12 months: Condom use in the past 12 months: Women: 18.7 % [17, 18]
Women: 1.10 Women: 30.8 % Men: 27 %
Men: 1.23 Men: 34.5 %
aThe number of months varies according to behavioral surveys in the different countries
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CSW - from the core group, and with his spouse - from
the general population).
The issue of scale-free networks and the way in which
they affect HIV epidemic spread is still an under-
explored area. In the context of Israel, the question is
what factors are related to the low level of HIV, and par-
ticularly among female heterosexual women, and how
we can explain results such as those described in
Table 1.
In Israel, the theoretical possibility that female hetero-
sexuals may have been infected through bisexual men is
probably of very limited impact. In fact, we know from a
web survey (n = 2,873) that 12 % of MSM reported having
sex both with men and women (bisexual men) [27].
Therefore, most HIV transmission in the group of female
heterosexuals in Israel is probably coming from the same
small group of heterosexuals, which may remain smallbecause of the protective effect of male circumcision. To
our knowledge, very few detailed studies exist in low
prevalence settings, and the Israeli data may therefore be
of great interest for future modeling of the impact of MC
on HIV transmission in low prevalence countries.
Also in the Netherlands, it appears that there is a lim-
ited virus transmission from MSM to the general het-
erosexual population, as shown in molecular
epidemiological studies on HIV and hepatitis B, but
cross-border travelling and migration play a role in the
heterosexual HIV transmission [28]. In the Netherlands,
sexual mixing patterns have also been studied between
and within ethnic groups (disassortative respectively as-
sortative mixing). Mathematical models showed that
despite the presence of ethnic minority populations
from HIV endemic countries, the heterosexual HIV epi-
demic is relatively stable and heterosexual transmission
occurs mostly within migrant communities. Migrants
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among the general heterosexual population [29].
Aiming to analyze the potential impact of MC in low
prevalence populations, and in order to prevent recruit-
ment bias of categories with different risk of HIV infec-
tion, we studied potential limitations, such as: 1) improper
estimation of MC in the three countries; 2) recruitment
biases; 3) sexual behaviour patterns and HIV testing strat-
egies; 4) economic development and access to cART, and
5) estimations of percentage of PLWHIV unaware of their
HIV status.
Concerning circumcision estimations, our evaluation is
precise for Israel but data for France and the Netherlands
were not readily available. Nevertheless, considering that
the circumcision rate in Israel is approaching 90 % but less
than 10 % in France and the Netherlands, it is probably a
quite good hypothesis to formulate so, and such difference
allowed us to compare between these countries.
To avoid selection biases, we included only cases of het-
erosexual HIV transmission not originating from countries
with generalized epidemics (GE). This was in spite of to the
fact that heterosexual ‘epidemics’ in Western Europe is
linked with the HIV epidemic in countries with GE. How-
ever, patterns of migration are different in each country,
with varying proportions of cases from different countries
of origin. In addition, we were not able to obtain data on
the circumcision status of heterosexuals originated from
GE but living in these three countries, and therefore we
preferred to exclude this group.
We also excluded individuals classified as one of the
classic high risk group for HIV transmission (MSM, IDU).
Regarding HIV testing strategies, despite the fact that
France may have theoretically been able to diagnose a
larger proportion of HIV cases (due to its highest num-
ber of tests done by 1,000 population on Europe), data
showed in Table 3 that the percentages of HIV tests that
people underwent (both among women and men) in the
past year were in fact lower than those performed in
Israel. However, this may be due to an older population
mix in France compared to Israel.
The three countries are quite comparable in terms of
clinical management (well covered by health insurance,
or even free of charge, with a wide availability of HIV
testing and cART treatment). Compared to developing
countries, access to cART in Israel, the Netherlands and
France is expected to be highly sufficient. However,
within and possibly also between countries the use of
treatment facilities (the time span between HIV diagno-
ses and entering HIV care) may differ between risk
groups and ethnic minorities.
A potentially important difference is related to the
level of economic development (as indicated by the GNI
per capita), that may affect the coverage of health care
services and the degree to which countries can invest inHIV control activities. However, the three countries are
categorized by World Bank as being of high income
countries, and access to HIV care between these coun-
tries seems similar [14].
Conclusion
In conclusion, differences in HIV rates among heterosex-
ual born in Israel, the Netherlands and France, may poten-
tially be explained by MC routinely practiced in Israel.
However, recommendation for systematic MC in low HIV
prevalence countries, which do not have such cultural
practices, needs further investigation, particularly consid-
ering the risk of developing a false sense of security and of
neglecting condom use.
Key-points
 By comparing nationwide HIV data from Israel, a
country where almost all males are circumcised, to
the Netherlands and France, where only minorities
of males are circumcised, we showed that global
annual rates of new HIV diagnoses were much
lower in Israel, both among men and women.
 Whereas the protective effect of male
circumcision (MC) on HIV prevalence has been
demonstrated in high prevalence countries, this is
the first time that such results may be observed in
the general heterosexual population in a low HIV
endemic country.
 The driving forces of an HIV epidemic in general and
the situation in countries with very low HIV
prevalence such as Israel were analyzed. In Israel, most
HIV transmission in the group of female heterosexuals
is probably coming from the same small group of
heterosexuals, which may remain small because of the
protective effect of male circumcision.
 Differences in HIV rates among heterosexuals living
in Israel, the Netherlands and France might be
explained by MC routinely practiced in Israel, since
other parameters of influence on HIV transmission
were rather similar between the countries.
 Despite the present findings, public health
recommendations for systematic MC in low HIV
prevalence countries, which do not have such
cultural practices, needs further investigations,
particularly considering the risk of developing a false
sense of security and of neglecting condom use.
What the outcomes will be, preventive strategies for
HIV should always be delivered as a “package”,
including counseling [30].
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